drugset
drugset / Trial / NCT03794960

Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)

NCT03794960 ↗

Phase 2 Withdrawn Tolerion, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial in subjects with established T1D.

Timeline

Start
2019-12-14
Primary completion
2021-12-14
Completion
2023-12-14

Outcome

Outcome not reported

Stopped: “Modification to Clinical Development Plan”

Drugs

EvaluationDrugModalityDoseRoute
Subject TOL-3021 Other / unclassified — —

Indications

type 1 diabetes mellitus